EXECUTIVE ENGAGEMENTS
OUTREACH
10129
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1213
Interactions with Platform & by Email
PARTICIPANTS
304
Unique # Participated
VALIDATIONS
96
Responses Validated*
COMPETITORS
71
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
74
PAGES
175
EDITION
18
PRICE
USD $5600
*Engagement stats are ongoing and dynamic
HIGHLIGHTS
Amid the COVID-19 crisis, the global market for Biosimilars estimated at US$7.5 Billion in the year 2020, is projected to reach a revised size of US$45.5 Billion by 2027, growing at a CAGR of 29.3% over the analysis period 2020-2027. Recombinant Non-glycosylated Proteins, one of the segments analyzed in the report, is projected to record a 28.9% CAGR and reach US$19.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Recombinant Glycosylated Proteins segment is readjusted to a revised 33.4% CAGR for the next 7-year period.
The Biosimilars market in the U.S. is estimated at US$2.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.8 Billion by the year 2027 trailing a CAGR of 28.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 26.1% and 25.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 20.7% CAGR.
In the global Recombinant Peptides segment, USA, Canada, Japan, China and Europe will drive the 23.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.4 Billion in the year 2020 will reach a projected size of US$6.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5.4 Billion by the year 2027.
SELECT PLAYERS
Allergan Plc; Amgen Inc.; Biocon Ltd.; Biopartners GmbH; Boehringer Ingelheim International GmbH; Celltrion Inc.; Dr. Reddy`s Laboratories Ltd.; Eli Lilly and Company; Fresenius Kabi; Intas Pharmaceuticals Ltd.; Mylan NV; Pfizer Inc.; Samsung Bioepis Co. Ltd.; Sandoz International GmbH; STADA Arzneimittel AG; Teva Pharmaceutical Industries Ltd.
SEGMENTS
» Product Type (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides) » Disease (Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases, Other Diseases)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Biosimilars: An Introductory Prelude |
| Recent Market Activity |
| World Healthcare Sector Gears Up for Biosimilar Wave |
| Biosimilars Offer Great Promise Despite Challenges |
| The US & Europe Drive Momentum in Worldwide Biosimilars Sales |
| Emerging Markets also Offer Robust Growth Opportunities |
| R&D Funding: Crucial for Future Expansion of Biosimilars Market |
| Prevailing Economic Scenario Favors Funding Pattern |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Allergan Plc (Ireland) |
| Amgen, Inc. (USA) |
| Biocon Ltd. (India) |
| Biopartners GmbH (Switzerland) |
| Boehringer Ingelheim International GmbH (Germany) |
| Celltrion, Inc. (South Korea) |
| Dr. Reddy's Laboratories Ltd. (India) |
| Eli Lilly and Company (USA) |
| Fresenius Kabi (Germany) |
| Intas Pharmaceuticals Ltd. (India) |
| Mylan N.V. (USA) |
| Pfizer, Inc. (USA) |
| Samsung Bioepis Co., Ltd. (Korea) |
| Sandoz International GmbH (Germany) |
| STADA Arzneimittel AG (Germany) |
| Teva Pharmaceutical Industries Ltd. (Israel) |
| 3. MARKET TRENDS & DRIVERS |
| Slew of Product Approvals Scale Up Market Revenues |
| Biosimilar Approvals in Europe (as of H1 2018) |
| Biosimilar Approvals in the US (as of H1 2018) |
| Pipeline Biosimilar Products in the US (as of H1 2018) |
| Biosimilar Approvals in South Korea (as of H1 2018) |
| Patent Expiry of Major Biopharmaceutical Drugs Leads Way for Biosimilars |
| Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe |
| Cost Containment Measures Put Focus on Biosimilars |
| High Cost of Biologics - Favorable for Biosimilars |
| Efforts to Push Up Biosimilar Adoption Aid Market Expansion |
| Increasing Share of Biotech Drugs to Drive Biosimilars Market |
| Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues |
| Specific Guidelines for Biosimilars in Various Countries with Year of Publication |
| Biosimilars Regulatory Agencies in Select Regional Markets |
| Improvement in Nomenclature & Interchangeability Enhance Appeal & Image of Biosimilars |
| Human Insulin Biosimilars Eye Potential Opportunities |
| Monoclonal Antibodies - A Key Segment for Biosimilars |
| Approved Monoclonal Antibodies (2014-2017) |
| Rituximab Biosimilars to Proliferate the Market |
| Growing Incidence of Chronic Diseases & Ageing Population Widen Prospects for Biosimilars |
| Growing Biosimilars Market - A Clear Advantage for Bioseparation Technologies |
| Growth Restraints |
| Lack of Uniform Regulations |
| High Lead-time |
| High Manufacturing Costs |
| Difficulties in Delivery & Commercialization |
| Automatic Substitution |
| Biobetters: A Potential Industry Challenge |
| Other Impediments to Market Acceptance |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
| World Current & Future Analysis for Recombinant Non-glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Recombinant Non-glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Recombinant Glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Recombinant Glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Recombinant Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Recombinant Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Blood Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Blood Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Chronic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Chronic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Autoimmune Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| USA Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| Canada Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| Japan Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| China Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Biosimilars by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
| Europe Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| Europe Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| France Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| Germany Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| Italy Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| UK Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 71 |
Tapping into New Geographical Markets is a Great Way to Grow!
What's Your Addressable Opportunity in the Biosimilars Market?
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com